Go Pro
NASDAQ:TNFA

TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis

TNF Pharmaceuticals logo
$2.92 +0.12 (+4.29%)
As of 08/7/2026

About TNF Pharmaceuticals Stock (NASDAQ:TNFA)

Advanced

Key Stats

Today's Range
$2.80
$2.99
50-Day Range
$2.51
$4.37
52-Week Range
$0.04
$8.94
Volume
106,732 shs
Average Volume
32.22 million shs
Market Capitalization
$5.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Receive TNFA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TNF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TNFA Stock News Headlines

Why did QCLS stock surge over 60% today?
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Headlines

TNFA Stock Analysis - Frequently Asked Questions

TNF Pharmaceuticals' stock was trading at $3.99 at the beginning of 2026. Since then, TNFA stock has decreased by 26.8% and is now trading at $2.92.

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) announced its quarterly earnings results on Tuesday, August, 19th. The company reported ($18.00) earnings per share for the quarter.

TNF Pharmaceuticals shares reverse split on the morning of Tuesday, September 2nd 2025.The 1-100 reverse split was announced on Thursday, August 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of TNFA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TNF Pharmaceuticals investors own include Amprius Technologies (AMPX), Archrock (AROC), Axon Enterprise (AXON), PACCAR (PCAR), Bitfarms (BITF), Bitfarms (BFARF) and BigBear.ai (BBAI).

Company Calendar

Last Earnings
8/19/2025
Today
8/09/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Technology Hardware, Storage & Peripherals
Sub-Industry
Technology Hardware, Storage & Peripherals
Current Symbol
NASDAQ:TNFA
Previous Symbol
NASDAQ:MYMD
CIK
1321834
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($231.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$23.36 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.21%
Return on Assets
-33.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.93
Quick Ratio
0.93

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$286.76 per share
Price / Book
0.01

Miscellaneous

Outstanding Shares
1,847,000
Free Float
1,839,000
Market Cap
$5.39 million
Optionable
N/A
Beta
2.04
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:TNFA) was last updated on 8/9/2026 by MarketBeat.com Staff.
From Our Partners